Evangelische Lungenklinik Berlin

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Lung cancer6 trials
• Idiopathic pulmonary fibrosis1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 35 trials
• Phase 22 trials

Status

• Recruiting4 trials
• Active, not recruiting1 trial
• Completed1 trial
• Not yet recruiting1 trial
• Terminated1 trial

Lead sponsor

• Dizal Pharmaceuticals1 trial
• Eli Lilly and Company1 trial
• ImmunityBio, Inc.1 trial
• Ipsen1 trial
• Lung Cancer Group Cologne1 trial
• and 3 more

Running trials

• Recruiting

  Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment

  NCT07314164· Ipsen· Source

  Contact: Ipsen Clinical Study Enquiries

• Recruiting

  A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

  NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source

• Recruiting

  Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy

  NCT06745908· Phase 3· ImmunityBio, Inc.· Source

• Recruiting

  Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  NCT06890598· Phase 3· Eli Lilly and Company· Source

  Contact: Christian Grohe (principal investigator)

• Recruiting

  LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

  NCT06216301· Phase 3· NovoCure GmbH· Source

  Contact: Norman von-Palubitzki

• Active, not recruiting

  A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

  NCT05668988· Phase 3· Dizal Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer4 recruiting
• Neuroendocrine tumours1 recruiting

Closed trials

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer

  NCT03083691· Phase 2· Lung Cancer Group Cologne· Source